Five Years of Purposeful Fashion: LILYSILK Renews Partnership with National Breast Cancer Foundation for ‘A Bloom of Care’ Campaign
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- LILYSILK, the world's leading silk brand dedicated to inspiring people to live spectacularly, announced the renewal of its partnership with National Breast Cancer Foundation, Inc.® (NBCF) through a new campaign, "A Bloom of Care," featuring a new sleepwear collection inspired by the lily flower. LILYSILK Renews Partnership with National Breast...
A Formidable Type of Childhood Cancer Gets Added to Highly Regarded Library of Treatment Recommendations
New NCCN Guidelines for Pediatric Bone Sarcoma focus on how to provide the best care possible for children and adolescents with Ewing sarcoma. PLYMOUTH MEETING, Pa., Oct. 1, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) published the first-ever edition of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for...
Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data
First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration subcutaneous formulation designed to combine BBT001's emerging profile of rapid, deep and durable clinical activity with convenient administration and the potential for infrequent maintenance dosing Milestone demonstrates continued execution of Bambusa's strategy...
Advances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial Efficiency
Supporting pharmaceutical, medical device, wellness, and research organizations in obtaining standardized sleep data Expanding the use of SOMNUM scoring technology to provide clinical analysis services tailored to each customer's research objectives AI Technologies Supporting Global Clinical Trials in Drug Development BOSTON, Oct. 1, 2026 /PRNewswire/ -- More pharmaceutical companies and research organizations are...
PeKa B40 Screenings Reveal Undiagnosed Conditions Among Almost Half of Participants
STR recipients and their spouses aged 40 and above urged to use their free health-screening benefit at participating clinics nationwide. CYBERJAYA, Malaysia, Oct. 1, 2026 /PRNewswire/ -- Of the 328,302 people who underwent health screening through PeKa B40 in 2025, 44.5% were found to have at least one previously undetected health concern, according to programme data. PeKa B40 Screenings...
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company's next phase of growth. Michael Stibilj, Emerald Clinical Trials Michael...
IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution
SYDNEY, Oct. 1, 2026 /PRNewswire/ -- IMG (International Medical Group) is excited to announce the successful completion of its acquisition of World Nomads. First announced in February 2026, the acquisition strengthens IMG's global travel insurance distribution capabilities and expands its presence in key international markets. World Nomads serves travelers from...
Health In Tech Launches HitRix to Modernize the Nearly $1 Trillion U.S. Self-Funded Health Insurance Market and Announces Updated 2026 Full-Year Revenue Guidance
AI-powered HitRix platform streamlines large-group submissions, multi-market quoting, proposal comparison and placement in one secure environment, thereby reducing time to market. STUART, Fla., Oct. 1, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company ("Health In Tech" or the "Company"), today announced the launch of...
Suvoda’s latest platform release creates a global experience across study data, patient engagement, scheduling, payments, and clinical trial operations
CONSHOHOCKEN, Pa., Sept. 30, 2026 /PRNewswire/ -- Suvoda, a global clinical trial technology company, today announced a new release of important advancements since unifying the market-leading Suvoda and Greenphire products on one platform. Innovations in AI and new product functionality are expanding the platform's capabilities, reducing manual work for users, and giving...
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturing activities are being conducted at Piramal's dedicated sterile injectable facility in Lexington, Kentucky. This partnership addresses ongoing cyclophosphamide shortages and supply chain risks, safeguarding...
